CHR-3996: Optimised HDAC Inhibitor for Treatment of Cancers
Histone Deacetylases (HDACs) are a family of metalloenzymes that are able to Deacetylase Histones, leading to repression of gene expression. Inhibition of HDACs has been shown to impact multiple aspects of tumour progression. First generation HDAC inhibitors have demonstrated the clinical utility of this class, but in many cases lack optimal pharmaceutical characteristics. Chroma entered a potent, orally-active, pharmaceutically optimised HDAC inhibitor candidate into development during 2006. CHR-3996 is expected to enter clinical development during 2007.